Baird raised the firm’s price target on Blueprint Medicines (BPMC) to $135 from $127 and keeps an Outperform rating on the shares. The firm said 2025 guidance was a little soft but they are on a steady trajectory to $2B by 2030.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Strong Buy Rating for Blueprint Medicines: Ayvakit’s Growth Potential and Market Opportunities
- Blueprint Medicines Reports Strong Growth and Promising Outlook
- Blueprint Medicines: Positive Earnings Call Highlights Growth
- Strong Market Position and Growth Potential Drive Buy Rating for Blueprint Medicines
- Blueprint Medicines should be bought on any weakness, says Stifel